CALA: Updated Results from Phase 1 Study of Telaglenastat (CB-839) to be Presented at 2019 ASCO Genitourinary Cancer Symposium http://ir.calithera.com/news-releases/news-release-details/updated-results-phase-1-study-telaglenastat-cb-839-be-presented?field_nir_news_date_value[min]= link